RESUMEN

This study aimed to quantify the changes in corneal higher-order aberrations (HOAs) before and after treatment for infectious keratitis and verify the correlation between corneal HOAs and visual acuity. Corneal HOAs were analysed using swept-source anterior segment optical coherence tomography (AS-OCT). Ninety-eight eyes of 96 consecutive patients with infectious keratitis treated with topical eye drops were retrospectively evaluated. Corneal HOAs increased with the infection but decreased with infection resolution following antimicrobial treatment. Corneal HOAs became larger as the degree of corneal findings became more severe. The increase in HOAs of the total cornea was correlated with the decrease in visual acuity both before and after treatment (4 mm, ρ = 0.530 and 0.590; 6 mm, ρ = 0.479 and 0.567, respectively; all P < 0.0001). Furthermore, pretreatment HOA (anterior, 6 mm), pretreatment logMAR best spectacle-corrected visual acuity, and age were prognostic factors significantly associated with posttreatment visual acuity (ß = 0.31, P = 0.013; ß = 0.36, P < 0.0001; and ß = 0.35, P = 0.0007, respectively) (adjusted R2 = 0.474). These results indicate that corneal HOAs quantified using AS-OCT can be used as an objective index to evaluate corneal optical function during the treatment of infectious keratitis.

Asunto(s)

RESUMEN

Purpose: To investigate changes in higher order ocular aberrations (HOA) induced by the administration of 0.15% sodium hyaluronate tear enhancer (TE) and meibomian gland expression (ME) on the tear film of normal subjects. Methods: HOA values were obtained from the corneal surface (CS) and whole eye (WE), using a corneal topographer and Shack-Hartmann aberrometer, from both eyes of 50 subjects (25 females, mean age ± sd 32.5 ± 11.0 years, and 25 males, 33.88 ± 11.2 years) for two pupil sizes (3 and 6 mm) in a dark environment. One drop of Blink ContactsTM (Abbott Medical Optics) was instilled into the right eye and HOA measurements repeated after 30 s. After 1h, the meibomian glands of the left lower eyelid were gently squeezed and HOA measurements repeated after 30s. Results: There was no significant difference for CS and WE root mean square (RMS) HOAs between right and left eyes before (both pupil sizes) and after TE use or ME (3 mm pupil). For 6mm pupil, TE use significantly reduced the WE RMS HOA (p < 0.05, mean ± sd) for Z40 (0.297 ± 0.136 to 0.053 ± 0.069), and Z55 (0.221 ± 0.372 to 0.098 ± 0.121) while ME significantly increased CS RMS HOA (p < 0.05, mean ± sd) for Z3-3 (0.799 ± 1.178 to 1.302±1.991) and Z44 (0.594±1.184 to 0.988 ± 1.463). In general, the change in HOA was significantly correlated with the initial value before TE use or ME (p < 0.05). Conclusion: There were no detectable differences between right and left eyes. For the 6mm pupil, the tear enhancer tended to improve optical performance of the WE and meibomian gland expression tended to reduce the optical performance at the CS

Objetivo: Estudiar los cambios de las aberraciones oculares de alto orden (HOA) inducidas por la aplicación de las lágrimas artificiales con 0,15% de hialuronato sódico y la expresión de las glándulas de Meibomio (ME) en la película lagrimal en sujetos normales. Métodos: Se obtuvieron los valores de HOA de la superficie corneal (SC) y de la totalidad del ojo, utilizando un topógrafo corneal y un aberrómetro Shack-Hartmann, de ambos ojos de 50 sujetos (25 mujeres, edad media ± DE 32,5 ± 11 años, y 25 varones, 33,88 ± 11,2 años) para dos tamaños de pupila (3 y 6 mm) en un entorno oscuro. Se instiló una gota de Blink ContactsTM (Abbott Medical Optics) en el ojo derecho, repitiéndose las mediciones de HOA transcurridos 30 segundos. Al cabo de 1 hora, se presionaron suavemente las glándulas de Meibomio del párpado inferior del ojo izquierdo y se repitieron las mediciones de HOA al cabo de 30 segundos. Resultados: No se produjo diferencia significativa en el error cuadrático médio (RMS) de HOA de la superficie corneal y la totalidad del ojo entre los ojos derecho e izquierdo (ambos tamaños de pupila) antes o después del uso de las lágrimas artificiales o ME (pupila de 3 mm). Para pupilas de 6mm, el uso de lágrimas artificiales redujo significativamente el RMS de HOA de la totalidad del ojo (p< 0,05, media ± DE) para Z04 (de 0,297 ± 0,136 a 0,053 ± 0,069), y Z55 (de 0,221 ± 0,372 a 0,098 ± 0,121) mientras que ME incrementó significativamente el RMS de HOA (p < 0,05, media ± DE) para Z−33 (de 0,799 ± 1,178 a 1,302 ± 1,991) y Z44 (de 0,594 ± 1,184 a 0,988 ± 1,463). En general, el cambio de HOA guardó una correlación significativa con el valor inicial antes del uso de lágrimas artificiales o ME (p < 0,05). Conclusión: No se observaron diferencias detectables entre los ojos derecho e izquierdo. Para la pupila de 6 mm, la lágrima artificial tendió a mejorar el rendimiento óptico de la totalidad del ojo, y la expresión de las glándulas de Meibomio tendió a reducir el rendimiento óptico de la superficie corneal

Asunto(s)

RESUMEN

PURPOSE: To investigate changes in higher order ocular aberrations (HOA) induced by the administration of 0.15% sodium hyaluronate tear enhancer (TE) and meibomian gland expression (ME) on the tear film of normal subjects. METHODS: HOA values were obtained from the corneal surface (CS) and whole eye (WE), using a corneal topographer and Shack-Hartmann aberrometer, from both eyes of 50 subjects (25 females, mean age±sd 32.5±11.0 years, and 25 males, 33.88±11.2 years) for two pupil sizes (3 and 6mm) in a dark environment. One drop of Blink Contacts™ (Abbott Medical Optics) was instilled into the right eye and HOA measurements repeated after 30s. After 1h, the meibomian glands of the left lower eyelid were gently squeezed and HOA measurements repeated after 30s. RESULTS: There was no significant difference for CS and WE root mean square (RMS) HOAs between right and left eyes before (both pupil sizes) and after TE use or ME (3mm pupil). For 6mm pupil, TE use significantly reduced the WE RMS HOA (p<0.05, mean±sd) for Z40 (0.297±0.136 to 0.053±0.069), and Z55 (0.221±0.372 to 0.098±0.121) while ME significantly increased CS RMS HOA (p<0.05, mean±sd) for Z3-3 (0.799±1.178 to 1.302±1.991) and Z44 (0.594±1.184 to 0.988±1.463). In general, the change in HOA was significantly correlated with the initial value before TE use or ME (p<0.05). CONCLUSION: There were no detectable differences between right and left eyes. For the 6mm pupil, the tear enhancer tended to improve optical performance of the WE and meibomian gland expression tended to reduce the optical performance at the CS.

Asunto(s)

RESUMEN

PURPOSE: To investigate the effects of a single instillation of hypotonic 0.18% sodium hyaluronate artificial tears on wavefront aberrations in dry eye patients. METHODS: Fifty patients with dry eye were recruited into this single-center, prospective, double-masked, randomized controlled trial. Patients were randomly assigned to receive one drop of preservative-free, hypotonic 0.18% sodium hyaluronate (treatment) in one eye and one drop of sterile 0.9% sodium chloride solution (control) in the other eye. Ocular aberrations evaluated by a Hartmann-Shack aberrometer and severity of dry eye symptoms graded by a questionnaire (at baseline, 1, 10, 30, 60, and 120 minutes after instillation) were the main outcome measures. RESULTS: After a single instillation of one drop of the allocated eye drops, there were no statistically significant differences between the treatment and control groups in total higher-order aberrations, coma, and spherical aberrations during the study period (p = 0.40, 0.57, and 0.16, respectively). Although a statistically significant (p = 0.04) decrease from baseline in spherical aberrations was noted in the treatment group at 1 minute following instillation, it gradually increased back to baseline values at later time points. A statistically significant diminishment of dry eye symptoms compared with the placebo was reported at all time points by the treatment group (p < 0.001). CONCLUSIONS: A single instillation of hypotonic 0.18% sodium hyaluronate eye drops is safe and effective in alleviating subjective dry eye symptoms; however, it does not appear to affect higher-order aberrations in moderate to severe dry eye patients.

Asunto(s)

RESUMEN

PURPOSE: The aim was to report the corneal higher-order aberrations (HOA), the topographic metrics, and the visual and refractive outcomes 2 years after performing collagen crosslinking (CXL) for progressive keratoconus. The correlation among corneal HOAs, topographic metrics, and visual acuity changes was also investigated. METHODS: This is a prospective case series involving 42 eyes from 32 patients with progressive keratoconus treated with CXL. The main outcomes measured at baseline and 6, 12, and 24 months after treatment were uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), refractive changes, topographic data, and corneal aberrations. RESULTS: Two years after CXL treatment, the UDVA (P < 0.001), CDVA (P < 0.001), and spherical equivalent (P = 0.048) improved significantly. The corneal topographic data revealed significant decreases in apical keratometry (P < 0.001), differential keratometry (P = 0.031), and central keratometry (P = 0.003) compared with the baseline measurements. Aberration analyses revealed a significant reduction in coma (P = 0.016), trefoil (P = 0.018), secondary astigmatism (P < 0.001), quatrefoil (P = 0.031), secondary coma (P < 0.001), and secondary trefoil (P = 0.001). Corneal HOA (except quatrefoil) demonstrated a significant correlation with postoperative CDVA; the highest correlations were for coma (rho = 0.703, P < 0.001), secondary astigmatism (rho = 0.519, P = 0.001), and total HOA (rho = 0.487, P = 0.001). However, the corneal HOA changes were not statistically associated with improved visual acuity. After treatment, the reduction in apical keratometry was the only variable that correlated with the improvement in the CDVA (rho = 0.319, P = 0.042). CONCLUSIONS: After 2 years, CXL was found to be effective in improving the UDVA, CDVA, topographic metrics, and most corneal HOAs in eyes with progressive keratoconus. A significant reduction was observed in apical keratometry, and this reduction directly correlated with an improvement in visual acuity.

Asunto(s)

RESUMEN

Corneal scarring remains a major cause of blindness world-wide, with limited treatment options, all of which have side-effects. Here, we tested the hypothesis that topical application of Rosiglitazone, a Thiazolidinedione and ligand of peroxisome proliferator activated receptor gamma (PPARγ), can effectively block scar formation in a cat model of corneal damage. Adult cats underwent bilateral epithelial debridement followed by excimer laser ablation of the central corneal stroma to a depth of ~160 µm as a means of experimentally inducing a reproducible wound. Eyes were then left untreated, or received 50 µl of either 10 µM Rosiglitazone in DMSO/Celluvisc, DMSO/Celluvisc vehicle or Celluvisc vehicle twice daily for 2 weeks. Cellular aspects of corneal wound healing were evaluated with in vivo confocal imaging and post-mortem immunohistochemistry for alpha smooth muscle actin (αSMA). Impacts of the wound and treatments on optical quality were assessed using wavefront sensing and optical coherence tomography at 2, 4, 8 and 12 weeks post-operatively. In parallel, cat corneal fibroblasts were cultured to assess the effects of Rosiglitazone on TGFß-induced αSMA expression. Topical application of Rosiglitazone to cat eyes after injury decreased αSMA expression and haze, as well as the induction of lower-order and residual, higher-order wavefront aberrations compared to vehicle-treated eyes. Rosiglitazone also inhibited TGFß-induced αSMA expression in cultured corneal fibroblasts. In conclusion, Rosiglitazone effectively controlled corneal fibrosis in vivo and in vitro, while restoring corneal thickness and optics. Its topical application may represent an effective, new avenue for the prevention of corneal scarring with distinct advantages for pathologically thin corneas.

Asunto(s)

RESUMEN

OBJETIVO: Avaliar as aberrações ópticas de alta ordem em pacientes com distonias faciais tratados com toxina botulínica tipo A. MÉTODOS: Pacientes com diagnóstico clínico de espasmo hemifacial ou blefaroespasmo essencial em atividade foram submetidos ao exame biomicroscópico e à análise de frente de ondas através do aberrômetro Alcon LADARvision®, sob midríase medicamentosa. A seguir, foram tratados com injeções de toxina botulínica tipo A. Após um mês, a análise de frente de ondas foi repetida da mesma forma e pelo mesmo oftalmologista. As aberrações de alta ordem foram comparadas antes e após o tratamento. O teste T pareado foi utilizado para comparar os valores numéricos antes e após o tratamento. RESULTADOS: Foram incluídos no estudo um total de 11 pacientes, 6 com blefaroespasmo essencial (54,5 por cento) e 5 com espasmo hemifacial (45,5 por cento). Nos pacientes com espasmo hemifacial foram analisados apenas o lado acometido, totalizando 17 olhos com espasmo. A idade variou de 50 a 72 anos, com média de 65,9 ± 8,2 anos. Oito pacientes eram do sexo feminino (72,7 por cento), sendo a relação masculino/feminino de 1:2,6. A média do "root mean square" (RMS) das aberrações de alta ordem foi 0,68 antes e 0,63 após um mês do tratamento (p=0,01). A média da aberração esférica foi de 0,23 e 0,17 antes e após o tratamento respectivamente (p=0,01). Não houve diferenças estatisticamente significantes nos demais tipos de aberrações de alta ordem após o tratamento (p>0,05). CONCLUSÃO: O tratamento com toxina botulínica A pode diminuir as aberrações esféricas em pacientes com distonias faciais.

PURPOSE: To analyze the ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin A. METHODS: Patients with benign essential blepharospasm and hemifacial spasm in activity underwent slit lamp examination and bilateral wavefront analysis under pharmacologic mydriasis using Alcon LADARvision® wavefront aberrometry system. After that, all patients were treated with botulinum toxin A injections performed by the same ophthalmologist. After one month, the wavefront analysis was performed in the same way and by the same examiner. The main outcome measure was the change in ocular wavefront aberrations. Paired T-test was used to compare pre and post-injection numeric wavefront values. RESULTS: From a total of 11 patients enrolled in this study, 6 (54.5 percent) had essential blepharospasm and 5 (45.5 percent) had hemifacial spasm. The fellow eyes of patients with hemifacial spasm were not included, totalizing 17 eyes with spasm. Eight patients were female (72.7 percent) and three were male (27.3 percent), the male:female ratio was 1:2.6. The age ranged from 50 to 72 years old with a mean of 65.9 ± 8.2 years. The mean of high order root mean square (RMS) wavefront aberrations was 0.68 before and 0.63 one month after the treatment (p=0.01). Before the treatment, the mean of spherical aberration was 0.23 and decreased to 0.17 one month after the treatment (p=0.01). There was no significant difference in the other higher-order aberrations before and after the treatment (p>0.05). CONCLUSION: The treatment with botulium toxin may decrease spherical aberrations in patients with facial dystonia.

Asunto(s)

RESUMEN

PURPOSE: To analyze the ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin A. METHODS: Patients with benign essential blepharospasm and hemifacial spasm in activity underwent slit lamp examination and bilateral wavefront analysis under pharmacologic mydriasis using Alcon LADARvision wavefront aberrometry system. After that, all patients were treated with botulinum toxin A injections performed by the same ophthalmologist. After one month, the wavefront analysis was performed in the same way and by the same examiner. The main outcome measure was the change in ocular wavefront aberrations. Paired T-test was used to compare pre and post-injection numeric wavefront values. RESULTS: From a total of 11 patients enrolled in this study, 6 (54.5%) had essential blepharospasm and 5 (45.5%) had hemifacial spasm. The fellow eyes of patients with hemifacial spasm were not included, totalizing 17 eyes with spasm. Eight patients were female (72.7%) and three were male (27.3%), the male:female ratio was 1:2.6. The age ranged from 50 to 72 years old with a mean of 65.9 ± 8.2 years. The mean of high order root mean square (RMS) wavefront aberrations was 0.68 before and 0.63 one month after the treatment (p=0.01). Before the treatment, the mean of spherical aberration was 0.23 and decreased to 0.17 one month after the treatment (p=0.01). There was no significant difference in the other higher-order aberrations before and after the treatment (p>0.05). CONCLUSION: The treatment with botulium toxin may decrease spherical aberrations in patients with facial dystonia.

Asunto(s)

RESUMEN

AIMS: To investigate the influence of 0.5% timolol gel-forming solution on ocular wavefront aberrations. METHODS: In 17 normal volunteers, ocular aberration was assessed before and 5 min, 30 min, 1 h, 2 h, 3 h, 6 h and 12 h after instillation of timolol gel-forming solution. Ocular aberration was sequentially measured over a period of 10 s, and the root-mean-square (RMS) of the second-, third-, fourth- and total higher-order aberrations (HOAs) were determined. From the time course of changes in total HOAs in 10 s, the stability index (SI) and fluctuation index (FI) were calculated. The authors also investigated sequential changes in specific Zernike components such as vertical coma, horizontal coma and spherical aberration. RESULTS: No significant changes in second-order RMS were observed (p=0.452, repeated-measures ANOVA). Topical instillation significantly increased HOAs such as third-, fourth- and total higher-order RMS (p=0.023, p=0.007 and p=0.003, respectively). Multiple comparison analysis revealed significant increases in HOAs 5 min after instillation (p=0.005 for third-, p=0.001 for fourth- and p<0.001 for total higher-order RMS, Dunnett post hoc test). FI increased significantly 5 min after instillation (p=0.013), but SI did not change significantly. With respect to sequential changes in specific components, significant changes were observed in vertical coma (p=0.004, repeated-measures ANOVA) and horizontal coma (p=0.005), but not in spherical aberration. CONCLUSION: Instillation of timolol gel-forming solution significantly degrades optical quality of the eye for approximately 5 min by increasing HOAs, which may cause blurred vision.

Asunto(s)